Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Another older, small study of 32 older adults found that MK-677 boosted levels of growth hormone in participants to a level ...

For the second-straight season, one of Atlanta's key hitters received a suspension from MLB.

Modernizing biomanufacturing methods and reducing regulatory burdens are key landmarks on India’s roadmap for expanding biosimilars development.

Not enough time to squeeze in strength training? Think again. James Witts shares how to build muscle at home – no equipment ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.